GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Augmedix Inc (NAS:AUGX) » Definitions » Enterprise Value

AUGX (Augmedix) Enterprise Value : $113.21 Mil (As of Oct. 31, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Augmedix Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Augmedix's Enterprise Value is $113.21 Mil. Augmedix's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was $-21.24 Mil. Therefore, Augmedix's EV-to-EBIT ratio for today is -5.33.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Augmedix's Enterprise Value is $113.21 Mil. Augmedix's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was $-19.83 Mil. Therefore, Augmedix's EV-to-EBITDA ratio for today is -5.71.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Augmedix's Enterprise Value is $113.21 Mil. Augmedix's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was $51.58 Mil. Therefore, Augmedix's EV-to-Revenue ratio for today is 2.19.


Augmedix Enterprise Value Historical Data

The historical data trend for Augmedix's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Augmedix Enterprise Value Chart

Augmedix Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
- - 91.35 54.13 264.02

Augmedix Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 195.54 214.60 264.02 187.86 40.25

Competitive Comparison of Augmedix's Enterprise Value

For the Health Information Services subindustry, Augmedix's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Augmedix's Enterprise Value Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Augmedix's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Augmedix's Enterprise Value falls into.



Augmedix Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Augmedix's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Augmedix's Enterprise Value for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Augmedix  (NAS:AUGX) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Augmedix's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=113.211/-21.239
=-5.33

Augmedix's current Enterprise Value is $113.21 Mil.
Augmedix's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-21.24 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Augmedix's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=113.211/-19.827
=-5.71

Augmedix's current Enterprise Value is $113.21 Mil.
Augmedix's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-19.83 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Augmedix's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=113.211/51.582
=2.19

Augmedix's current Enterprise Value is $113.21 Mil.
Augmedix's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $51.58 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Augmedix Enterprise Value Related Terms

Thank you for viewing the detailed overview of Augmedix's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Augmedix Business Description

Traded in Other Exchanges
N/A
Address
111 Sutter Street, Suite 1300, San Francisco, CA, USA, 94104
Augmedix Inc is engaged in ambulatory/clinical/hospital segments of the U.S. patient care services market with products that address medical note documentation needs. The company's products cater to large and small healthcare organizations but can also be adopted by individual practitioners. The company products extract data from natural clinician-patient conversations and convert it in real time to medical notes, which are seamlessly transferred to the electronic health record (EHR). The company's revenues consist of service fees charged to its customers to subscribe to the company's remote medical documentation and clinical support products.
Executives
Paul Ginocchio officer: Chief Financial Officer C/O AUGMEDIX, INC., 111 SUTTER STREET, SUITE 1300, SAN FRANCISCO CA 94104
Saurav Chatterjee officer: CHIEF TECHNOLOGY OFFICER C/O AUGMEDIX, INC., 1161 MISSION STREET, SUITE LL, SAN FRANCISCO CA 94103
Emmanuel Krakaris director, officer: PRESIDENT, CEO, AND SECRETARY C/O AUGMEDIX, INC., 1161 MISSION STREET, SUITE LL, SAN FRANCISCO CA 94103
Ian Shakil officer: CHIEF STRATEGY OFFICER C/O AUGMEDIX, INC., 1161 MISSION STREET, SUITE LL, SAN FRANCISCO CA 94103
Sandra Breber officer: CHIEF OPERATING OFFICER C/O AUGMEDIX, INC., 1161 MISSION STREET, SUITE LL, SAN FRANCISCO CA 94103
Jonathan Hawkins officer: Chief Revenue Officer C/O AUGMEDIX, INC., 1161 MISSION STREET, SUITE LL, SAN FRANCISCO CA 94103
Redmile Group, Llc director, 10 percent owner ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Margie L. Traylor director 5130 E. CASCALOTE DR, CAVE CREEK AZ 85331
Redco Ii Master Fund, L.p. director, 10 percent owner ONE LETTERMAN DRIVE, BLDG D, STE D3-300, SAN FRANCISCO CA 94129
Robert C. Faulkner director C/O REDMILE GROUP, ONE LETTERMAN DRIVE, BUILDING D, SUITE D, SAN FRANCISCO CA 94129
Roderick H. O'reilly director C/O CHANGE HEALTHCARE INC., 3055 LEBANON PIKE, SUITE 1000, NASHVILLE TN 37214
Mckesson Ventures, Llc director, 10 percent owner ONE POST STREET, SAN FRANCISCO CA 94104
William J Febbo director 600 CALIFORNIA ST., 9TH FLOOR, SAN FRANCISCO CA 94108
Laurie Mcgraw director 4720 E COTTON GIN LOOP, SUITE 220, C/O MEDAVAIL HOLDINGS, INC., PHOENIX AZ 85040
Jason Krikorian director, 10 percent owner C/O AUGMEDIX, INC., 1161 MISSION STREET, SUITE LL, SAN FRANCISCO CA 94103